MENT - Methylnortestosterone Acetate
Standard Testosterone propionate
Chemical Name 19-norandrost-4-en-3-one-17beta-ol 17beta-hydroxy-estr-4-en-3-one
Estrogenic Activity Low
Progestational Activity Moderate
MENT, short for methylnortestosterone (acetate), is a synthetic anabolic steroid derived from nandrolone. This agent is also called trestolone acetate, although not as commonly. The trivial name methylnortestosterone is Historx; vague, and can also be applied to other steroids. In this case the "methyl" in the name, which is commonly associated with (-17 alpha alkylated androgens like methyltestosterone, methandrostenolone, or oxymetholone, is referring to a modification at (-7. This gives MENT a considerably different appearance than 17- methylnoretestosterone (Orgasteron). Of most obvious significance is its method of use. Although perhaps possessing a moderate level of oral bioavailability, this nandrolone derivative was not designed for oral administration. It is much more effective when administered to the body directly, by injection, implant, or transdermal gel. In character, MENT is a strongly anabolic steroid, which is accompanied by moderate androgenic and estrogenic properties.
MENT is a modified form of nandrolone. It differs by the addition of a methyl group at carbon 7-alpha to increase steroid potency and relative androgenicity. MENT generally refers to methylnortestosterone acetate, modified with the addition of carboxylic acid ester (acetic acid) at the l7-beta hydroxyl group to help extend the activity of the steroid during injection or implantation
MENT is not yet available as a prescription drug product.
MENT has not yet been developed into a commercial drug product. Prescribing guidelines are unavailable. MENT is a relatively potent steroid, so an effective dose for bodybuilders is going to be small. As a drug 10 times more anabolic than testosterone by some studies, and 20 times more effective at suppressing spermatogenesis than testosterone enanthate in others, we should commonly see daily doses under 10 mg (maybe 3-6mg most commonly). If prepared as an oil-based injectable (with acetate ester), this would mean shots of roughly 10-20 mg every two to three days. Compare this to trenbolone, which is usually given in doses of 75-100 mg per shot under the same schedule (and this is a particularly potent steroid). Some might find good effect at 10 mg daily or above, although high doses will likely amplify potential side effects, and are not recommended.
MENT should stack well with a variety of different steroids, possibly for both cutting and bulking phases of training depending on individual sensitivity to its estrogenic and progestational properties. For simplicity, this might mean using it with drugs like testosterone cypionate or enanthate (200-400 mg per week), Dianabol (20-35 mg per day), or Anadrol (50-100 mg per day) when looking for sheer size, milder anabolics like nandrolone decanoate or boldenone undecylenate (200-400 mg per week) for lean mass, or non-aromatizable drugs like Primobolan (200- 400 mg per week), Winstrol (20-35 mg per day), or Anavar (15-20 mg per day) while cutting. Remember that c-17 alpha alkylated substances impart some hepatotoxictiy, and may greatly amplify the negative effects of steroid therapy on serum lipids.
TwisT's Recommended Protocol:
As we have seen MENT is an extremely harsh compound, and one that I would personally not touch unless I was competing in some aspect. While I would not consider taking MENT and huge risk, you are really going to shut yourself down hard and you are in for some gyno issues. For the average AAS user I would recommend no more then 10mg/day (ideal) or 25mg EOD. Obviously, every day dosing would be preferred. For the more experienced competitor, I would cautiously recommend no more then 30mg/day, but I would do a much lower dose cycle first to see how your body reacts. Alongside these protocols, run letrozole, arimidex, or aromasin. I personally prefer aromasin as it is a suicidal AI, but with this compound some people may need a more powerful AI, in which case the ideal would be letrozole.
MENT has not yet been developed into a commercial drug product. Prescribing guidelines are unavailable. Given its high level of potency, effective doses in women would likely be measured in microgram amounts. The drug would also generally be taken in cycles lasting 4 weeks or less. Note that virilizing side effects are still possible with primarily anabolic substances, and need to be carefully monitored.
This is one of those compounds, in my opinion, that the risks really outweigh the rewards. Though the weight gain that has been reported and the anabolic effects that may seem to be extraordinary are present, some scary sides have been reported. The study that tells us MENT is 10x more anabolic then testosterone sadly has some more no-so-satisfying results. The study states that MENT is 10x as anabolic as testosterone, and 4x as androgenic, and also that MENT is 12x as suppressive to serum gonadatropins as testosterone. For this reason, it is very appealing to scientists who have studied it for use as a male contraceptive – and ended up calling it “The Optimal Androgen for Male Contraception” (Ann Med. 1993 Apr;25(2):199-205.). In addition, and partly owing to its inability to be 5a-reduced, MENT is converted (via the aromatase enzyme) to a very potent form of estrogen – which can cause gynecomastia (enlarged breast tissue in males), and several other nasty side effects.
Llewellyn’s W. (2009). Anabolics (9th ed), MENT (pp. 287-290): Jupiter, FL: Molecular Nutrition
Anthony Roberts on Aug 27th, 2010 steroidtimes.com Trestolone Acetate (MENT)
Last edited by TwisT; 12-26-2010 at 06:08 PM.
7Alpha-methyl-19-nortestosterone maintains sexual behavior and mood in hypogonadal men.
Anderson RA, Martin CW, Kung AW, Everington D, Pun TC, Tan KC, Bancroft J, Sundaram K, Moo-Young AJ, Baird DT.
Medical Research Council Reproductive Biology Unit, Center for Reproductive Biology, Edinburgh, Scotland. firstname.lastname@example.org
The synthetic steroid 7alpha-methyl-19-nortestosterone (MENT) is a potent androgen that is resistant to 5alpha-reductase. It thus has decreased activity at the prostate and may have advantages over testosterone-based regimens in long term treatment or as part of a male contraceptive. Administration to eugonadal men results in suppression of gonadotropins, but its ability to support androgen-dependent behavior has not been investigated. For sustained release administration, MENT acetate was used, because its diffusion characteristics were more suitable for use in implants. However, upon release the acetate is rapidly hydrolyzed, and MENT is the biologically active moiety in circulation. We studied the effects of MENT on sexual interest and activity, spontaneous erection, and mood states in comparison with testosterone enanthate (TE) in 20 Caucasian and Chinese hypogonadal men recruited in Edinburgh and Hong Kong (n = 10 in each center). Outcomes were measured using a combination of daily diaries, semistructured interviews, and questionnaires. Nocturnal penile tumescence (NPT) was also recorded in the Edinburgh group. After withdrawal of androgen replacement treatment (wash-out phase) for a minimum of 6 weeks, subjects were randomized to two groups in a cross-over design. Drug treatment regimens were of 6-week duration and consisted of two implants, each containing 115 mg MENT acetate, inserted s.c. into the upper arm and removed after 6 weeks and two injections of TE (200 mg, i.m.) 3 weeks apart. MENT treatment resulted in stable plasma MENT concentrations of 1.4 +/- 0.1 nmol/L after 3 weeks and 1.3 +/- 0.1 nmol/L after 6 weeks (mean +/- SEM; all men). Nadir testosterone concentrations were 3.6 +/- 0.6 nmol/L at the end of the wash-out phase and 9.4 +/- 0.6 nmol/L 3 weeks after each injection. There were no differences in hormone concentrations between centers. There were no adverse toxicological effects. There were only minor differences between the two treatments. Both MENT and TE treatment resulted in significant increases in sexual interest and activity, spontaneous erection (both by self-report and NPT measurement), and increases in positive moods, with decreases in negative moods in the Edinburgh group. In the Hong Kong group, both treatments increased waking erection, with a trend toward increased sexual interest and activity. Mood states appeared to be less affected during the wash-out phase than in Edinburgh men and showed no significant response to either treatment. These results demonstrate that MENT has similar effects on sexual activity and mood states as testosterone in hypogonadal men. As NPT is a physiological androgen-dependant outcome, these data provide further evidence for the androgenicity of MENT. The lack of detected effect of either androgen in Hong Kong men other than on waking erection illustrates the importance of the cultural context of symptomatology and its measurement. The appropriate dose of MENT remains to be determined, but these results support its development as a potential androgen replacement therapy.
PMID: 10522995 [PubMed - indexed for MEDLINE]
Dimethandrolone (7alpha,11beta-dimethyl-19-nortestosterone) and 11beta-methyl-19-nortestosterone are not converted to aromatic A-ring products in the presence of recombinant human aromatase.
Attardi BJ, Pham TC, Radler LC, Burgenson J, Hild SA, Reel JR.
Division of Reproductive Endocrinology and Toxicology, BIOQUAL Inc., 9600 Medical Center Drive, Rockville, MD 20850, USA. email@example.com
Dimethandrolone undecanoate (DMAU: 7alpha,11beta-dimethyl-19-nortestosterone 17beta-undecanoate) is a potent orally active androgen in development for hormonal therapy in men. Cleavage of the 17beta-ester bond by esterases in vivo leads to liberation of the biologically active androgen, dimethandrolone (DMA), a 19-norandrogen. For hormone replacement in men, administration of C19 androgens such as testosterone (T) may lead to elevations in circulating levels of estrogens due to aromatization. As several reports have suggested that certain 19-norandrogens may serve as substrates for the aromatase enzyme and are converted to the corresponding aromatic A-ring products, it was important to investigate whether DMA, the related compound, 11beta-methyl-19-nortestosterone (11beta-MNT), also being tested for hormonal therapy in men, and other 19-norandrogens can be converted to aromatic A-ring products by human aromatase. The hypothetical aromatic A-ring product corresponding to each substrate was obtained by chemical synthesis. These estrogens bound with high affinity to purified recombinant human estrogen receptors (ER) alpha and beta in competitive binding assays (IC50's: 5-12 x 10(-9) M) and stimulated transcription of 3XERE-luciferase in T47Dco human breast cancer cells with a potency equal to or greater than that of estradiol (E2) (EC50's: 10(-12) to 10(-11) M). C19 androgens (T, 17alpha-methyltestosterone (17alpha-MT), androstenedione (AD), and 16alpha-hydroxyandrostenedione (16alpha-OHAD)), 19-norandrogens (DMA, 11beta-MNT, 19-nortestosterone (19-NT), and 7alpha-methyl-19-nortestosterone (MENT)) or the structurally similar 19-norprogestin, norethindrone (NET) were incubated at 50 microM with recombinant human aromatase for 10-180 min at 37 degrees C. The reactions were terminated by extraction with acetonitrile and centrifugation, and substrate and potential product were separated by HPLC. Retention times were monitored by UV absorption, and UV peaks were quantified using standard curves. Aromatization of the positive controls, T, AD, and 16alpha-OHAD was linear for 40-60 min, and conversion of T or AD was complete by 120 min. The nonsteroidal aromatase inhibitor, letrozole, demonstrated concentration-dependent suppression of T aromatization. Under the same conditions, there was no detectable conversion of DMA, 11beta-MNT, or NET to their respective hypothetical aromatic A-ring products during incubation times up to 180 min. Aromatization of MENT and 19-NT proceeded slowly and was limited. Collectively, these data support the notion that in the absence of the C19-methyl group, which is the site of attack by oxygen, aromatization of androgenic substrates proceeds slowly or not at all and that this reaction is impeded by the presence of a methyl group at the 11beta position.
MENT in comparison to Testosterone
The ability of 7 alpha-methyl-19-nortestosterone acetate (MENT) to increase the weights of ventral prostate and seminal vesicles of castrated rats was four times higher than that of testosterone, while its effect on the weights of bulbocavernosus plus levator ani muscles (muscle), was 10 times that of testosterone.
(Endocrinology. 1992 Jun;130(6):3677-83.)
Is the shut down more than with tren
Anybody else find the fact that they just cut out muscle that you can't train and measure how much it weighs a superficial measure of anabolism? By that logic, anything that makes you retain water in your muscles must be really anabolic. Salt is suddenly twice as anabolic as testosterone on a mg basis. I'm thinking a better measure of anabolism, like protein content, or some measure of gene expression would be far more reliable.
By theCaptn' in forum Anabolic Zone
Last Post: 10-13-2014, 05:40 PM
By theCaptn' in forum Anabolic Zone
Last Post: 10-14-2011, 11:18 PM
By jaredw33 in forum NapsGear
Last Post: 07-08-2011, 07:37 AM
By Khoiktran in forum Anabolic Zone
Last Post: 04-09-2011, 10:25 AM
By ANIMALHAUS in forum Anabolic Zone
Last Post: 04-08-2011, 12:28 PM